AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2022 and recent updates. Second Quarter Fiscal Year 2023 and Subsequent Highlights: Completed dosing its randomized, double-blind, placebo-controlled Phase 2 trial evalua
The informative cannabis social network. Join groups, make friends and be part of the cannabis community! Share your recipes, product & strain reviews, tutorials and more! Log in or register to continue
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates
Stock Ticker
- Loading stock data...
Categories
Recent Posts
- HEXO Ranks on The Globe and Mail’s Fourth-Annual Women Lead Here Benchmark of Executive Gender Diversity
- Slice Onboards 4 New Distribution Partners for Small Business Insurance
- Adnant Consulting Transforms Unrivaled Brands With 41% Reduction in Debt in Bear Cannabis Market
- HEXO Reports Q2’23 Financial Results
- High Tide Reports Second Consecutive Quarter of Record Revenue and Adjusted EBITDA; $118 Million and $5.5 Million, Respectively
More from this user
